BINDING AGENT of Programmed cell death 1 ligand 1 binding agent
Product Description
Pacmilimab (anti-PD-L1) is a potent PD-L1 inhibitor. Pacmilimab (anti-PD-L1) shows antitumor activity. Purity ≥95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/m
Product Properties
Isotype
Human IgG4SP
Light Chain Type
kappa
SDS-PAGE
145 kDa
Purification Method
Protein A purified
Form
Liquid
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
2145091-51-4
Images
Pacmilimab (anti-PD-L1) (Ab182789) - Flow Cytometry Flow Cytometry analysis of unstimulated (left) or 500 ng/mL Ionomycin (I139530) and 10 ng/mL PMA (P408905) co-stimulated (right) Jurkat cells labelling PD-L1 (red) with Pacmilimab (anti-PD-L1) (Ab182789) at 0.1 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Pacmilimab (anti-PD-L1) (Ab182789) - ELISA Immobilized Recombinant Human PD-L1 protein (rp169666) at 1.0 μg/mL can bind Pacmilimab (anti-PD-L1) (Ab182789) with the EC
₅₀
of 1.2 μg/mL.
Pacmilimab (anti-PD-L1) (Ab182789) - SEC The purity of Pacmilimab (anti-PD-L1) (Ab182789) is more than 95% verified by HPLC.
Associated Targets
CD274Tclin Programmed cell death 1 ligand 1 0 Activities